Loading...
Loading...
BioMarin Pharmaceutical
Inc.
BMRN announced today that it has acquired Zacharon
Pharmaceuticals, a private biotechnology company based in San Diego focused on
developing small molecules targeting pathways of glycan and glycolipid
metabolism.
Zacharon drug discovery projects include two ongoing lead optimization
programs, inhibition of heparan sulfate synthesis for MPS III and other MPS
disorders, and inhibition of ganglioside synthesis for diseases such as Tay
Sachs and Sandhoff. Zacharon's proprietary SensiPro^® platform is a powerful
technology for analysis of specific carbohydrate structures and therefore the
identification of candidate drugs to treat those conditions.
Under the terms of the stock purchase agreement, BioMarin paid $10 million
upfront for 100 percent of Zacharon's share capital and may make potential
additional payments for clinical, regulatory and commercial milestones. The
costs to be incurred in 2013 of acquiring Zacharon and absorbing its
operations is covered by the previously provided 2013 R&D expense guidance.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in